Development and application of a flow cytometric potency assay for DNA vaccines

被引：12

作者：

Badger, C. V. ^{[1
]}

Richardson, J. D. ^{[1
]}

DaSilva, R. L. ^{[1
]}

Richards, M. J. ^{[1
]}

Josleyn, M. D. ^{[1
]}

Dupuy, L. C. ^{[1
]}

Hooper, J. W. ^{[1
]}

Schmaljohn, C. S. ^{[1
]}

机构：

[1] USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA

来源：

VACCINE | 2011年 / 29卷 / 39期

关键词：

Hemorrhagic fever with renal syndrome; Hantavirus; Venezuelan equine encephalitis virus; Potency assay; Flow cytometry; DNA vaccine; Gene gun; Electroporation; VIRUS;

D O I：

10.1016/j.vaccine.2010.12.053

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We have developed a rapid, reliable, and sensitive quantitative flow cytometric assay to measure the in vitro potency and stability of DNA vaccines to be delivered either by particle-mediated epidermal delivery (PMED) or by electroporation. The method involves transfecting cells with test DNA and comparing the measured antigen expression to that generated with expression from known quantities of reference material DNA. The assay was adapted for performance under Good Laboratory Practice (GLP) guidelines and was successfully utilized to perform potency testing in support of a Phase I study for two hantavirus DNA vaccines delivered by gene gun. The results from the potency assays conducted over a 24-month period using this method proved to be highly reproducible with high signal-to-noise ratios. The assay was also adapted to assess the in vitro potency and stability of a DNA vaccine for Venezuelan equine encephalitis virus that will be delivered by electroporation. Our results indicate that this assay can be readily applied to support potency and stability testing of numerous DNA vaccines delivered by various methods, including multiagent vaccines. Published by Elsevier Ltd.

引用

页码：6728 / 6735

页数：8

共 11 条

[1] CHARACTERIZATION OF HANTAAN VIRUS ENVELOPE GLYCOPROTEIN ANTIGENIC DETERMINANTS DEFINED BY MONOCLONAL-ANTIBODIES [J].

ARIKAWA, J ;

SCHMALJOHN, AL ;

DALRYMPLE, JM ;

SCHMALJOHN, CS .

JOURNAL OF GENERAL VIROLOGY, 1989, 70 :615-624

[2] The role of particle-mediated DNA vaccines in biodefense preparedness [J].

Dean, HJ ;

Haynes, J ;

Schmaljohn, C .

ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (09) :1315-1342

[3]

Dupuy LC, 2009, EXPERT REV VACCINES, V8, P1739, DOI [10.1586/erv.09.132, 10.1586/ERV.09.132]

[4] Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases [J].

Fuller, Deborah H. ;

Loudon, Peter ;

Schmaljohn, Connie .

METHODS, 2006, 40 (01) :86-97

[5] DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in rhesus monkeys [J].

Hooper, JW ;

Custer, DM ;

Thompson, E ;

Schmaljohn, CS .

JOURNAL OF VIROLOGY, 2001, 75 (18) :8469-8477

[6] Development of potency assays for a plasmid containing vascular endothelial growth factor 2 [J].

Huang, Li-chun ;

Chin, Emily ;

Chiang, Yawen L. .

ELECTRONIC JOURNAL OF BIOTECHNOLOGY, 2010, 13 (01)

[7] FDA guidance on prophylactic DNA vaccines: Analysis and recommendations [J].

Klinman, Dennis M. ;

Klaschik, Sven ;

Tross, Debra ;

Shirota, Hidekazu ;

Steinhagen, Folkert .

VACCINE, 2010, 28 (16) :2801-2805

[8] Human clinical trials of plasmid DNA vaccines [J].

Liu, Margaret A. ;

Ulmer, Jeffrey B. .

ADVANCES IN GENETICS, 2005, 55 :25-40

[9]

MATHEWS JH, 1982, J IMMUNOL, V129, P2763

[10] Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines [J].

Parreiras, P. M. ;

Sirota, L. A. ;

Wagner, L. D. ;

Menzies, S. L. ;

Arciniega, J. L. .

VACCINE, 2009, 27 (33) :4537-4542

← 1 2 →